1
Clinical Trials associated with NB005(NeoLogics Bioscience)一项评价NB005联合放疗在晚期或局部晚期实体瘤患者中的安全性、耐受性、药代动力学特征及初步有效性的I/II期临床研究
[Translation] A Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of NB005 combined with radiotherapy in patients with advanced or locally advanced solid tumors
评价NB005联合放疗的安全性及耐受性,并确定NB005联合放疗的最大耐受剂量(MTD)和II期推荐给药剂量(RP2D)。
[Translation] To evaluate the safety and tolerability of NB005 combined with radiotherapy, and to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of NB005 combined with radiotherapy.
100 Clinical Results associated with NB005(NeoLogics Bioscience)
100 Translational Medicine associated with NB005(NeoLogics Bioscience)
100 Patents (Medical) associated with NB005(NeoLogics Bioscience)
100 Deals associated with NB005(NeoLogics Bioscience)